Background and Aim: Breast carcinoma is the most common type of cancer and the most common cause of cancer-related mortality among women worldwide. Cancer stem cells (CSCs) are thought to be responsible for tumor initiation, progression, dissemination and resistance to chemotherapy and radiotherapy. CD133 is a trans-membrane glycoprotein which is considered as a putative CSCs marker. It has been extensively used as a stem cell marker for normal and cancerous tissues. Emerging evidence suggests that CD133 may be a critical factor in tumor development, progression and metastasis. The aim of this study was to evaluate expression status of CD133 in invasive ductal carcinoma (IDC) of the breast and its role during breast cancer progression and to correlate its expression with some known clinicopathological parameters.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
1. Detect the immunohistochemical expression of CD133 in mammary invasive ductal carcinoma (IDC) and to correlate its expression with some known clinicopathological parameters.
Timeframe: 1 month